Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

I said if they did an RS I expected on Friday this week but it had to be into a news event. That news event is either good AACR data and or FDA news as we must be around the 30 day response timeline that FDA have to reply after Advaxis submitted information.

I was highlighting that there is potential for shares to become scarce and with only 5 million or so shares that is pretty scarce if good news follows.